

Fig .1 RSV F AND TRIVALENT FLU VLP COMBINATION VACCINE




- S205 Monovalent Bulk Vaccine formulations were used to prepare Trivalent Flu VLP
- A/California/07/09, A/Victoria/210/09, B/Wisconsin/1/10 strains were used
- RSV F nanoparticle vaccine from a development lot 683.15p was used in combination vaccine

Fig. 2 EVALUATION OF RSV F SPECIFIC ANTIBODY RESPONSES




- Day 0, 21 and 35 serum samples were tested in RSV F IgG ELISA
- Day 0 serum sample titers were <100
- Day 21 and 35 serum samples had robust responses to RSV F antigen in ELISA
- RSV F + Flu combination vaccine is as immunogenic as the individual counterparts

Fig. 3. EVALUATION OF RSV NEUTRALIZING ANTIBODY RESPONSES




- Day 0, and 35 serum samples were tested in RSV neutralization assay
- Day 0 serum sample titers were <20
- Day 35 serum samples neutralized RSV virus at a titer of 95-226
- RSV F + Flu combination vaccine had most response compared to individual counterparts

Fig. 4. PALIVIZUMAB COMPETITIVE INHIBITION GMT




- Day 0, 21 and 35 serum samples were tested in Palivizumab competition ELISA
- Day 0 serum sample titers were <20
- Day 35 serum samples exhibited higher inhibition titers compared to day 21 serum samples
- RSV F + Flu combination vaccine had most response compared to individual counterparts

Fig. 5: A-CALIFORNIA HAI hemagglutination Inhibition assay




- Day 0, and 35 serum samples were tested in hemagglutination Inhibition assay
- Day 0 serum sample titers were <20
- Day 35 serum samples exhibited hemagglutination inhibition titers
- RSV F + Flu combination vaccine responses are equal compared to individual counterparts

Fig. 6: A/VICTORIA HAI hemagglutination Inhibition assay



- Day 0, and 35 serum samples were tested in hemagglutination inhibition assay
- Day 0 serum sample titers were <20
- Day 35 serum samples exhibited hemagglutination inhibition titers
- RSV F + Flu combination vaccine responses are equal compared to individual counterparts

Fig. 7: B/WISCONSIN HAI hemagglutination Inhibition assay



- Day 0, and 35 serum samples were tested in hemagglutination inhibition assay
- Day 0 serum sample titers were <20
- Day 35 serum samples exhibited hem agglutination inhibition titers
- RSV F + Flu combination vaccine responses are equal compared to individual counterparts

Fig. 8 Anti-F IgG Responses to Human Study Treatments




Fig. 9 Estimated Palivizumab- Like Antibody Concentrations by Competitive ELISA




Fig. 10 Titer of Serum IgG Binding to Antigenic Site II Peptide




Fig. 11A Evaluation of RSV F IgG Antibody Responses




Fig. 11B Tabular Data of RSV F IgG Antibody Responses

	RSV F			Q VLP (HA)			RSV F + Q VLP (HA)		
Dose (µg)	0.5	1.5	6.0	0.5	1.5	6.0	0.5	1.5	6.0
GMT	46,087	65,632	108,932	50	50	50	108,178	186,737	284,639
95% CI	18,572 114,366	33,161 129,898	54,901 216,136	-	-	-	75,665 154,662	127,737 272,989	223,418 362,637
Fold Rise							2.3	2.6	2.8
p value	p significance; combo versus single							*0.02	*0.04

Fig. 12A Analysis of palivizumab Competing Antibody Responses




Fig. 12B Tabular data showing palivizumab Competing Antibody Responses

	RSV F			Q VLP (HA)			RSV F + Q VLP (HA)		
Dose (µg)	0.5	1.5	6.0	0.5	1.5	6.0	0.5	1.5	6.0
GMT	55	76	95	20	20	20	125	166	268
95% CI	33-94	44-130	56-161				99-157	129-214	215-334
Fold Rise							2.25	2.18	2.8
p value	p significance; combo versus single						*0.007	*0.007	*0.003

Fig. 13A Analysis of RSV A Microneutralization titers




Fig. 13B Tabular data showing RSV A Neutralizing Antibody Responses

	RSV F			Q VLP (HA)			RSV F + Q VLP (HA)		
Dose (μg)	0.5	1.5	6.0	0.5	1.5	6.0	0.5	1.5	6.0
GMT	25	43	57	10	10	10	49	61	92
95% CI	18-34	32-57	32-102				35-69	47-78	58-145
Fold Rise							2.0	1.4	1.6
p value	p significance; combo versus single						*0.001	-	-

Fig. 14 Hemagglutinin Inhibition Test Reagents

Flu Strain Antigen	Flu virus HAI	HA Titer	Positive Control	HAI Positive control Titer
A/Cal/04/09 (H1N1)	A/CA/04/09 MD-5	128	A/CA/04/09 HA-Sheep	12,800
A/Vic/361/11(H3N2)	A/Vic/210/09 MD-3 1:100,000 36C	64	A/Vic HA-Sheep	6400
B/Bris/60/08	B/Bris/60/08 MD-4 10e6 031210	1,024(ether)	B/Bris HA708P-Sheep	6,400
B/Mass/2/12	B/Mass/2/12 10e6/4/12	3200 (ether)	B/Wis HA-Sheep	12,800




Fig. 15A HAI response against the A/California/04/09 strain

Fig. 15B Tabular Data for HAI response against the A/California/04/09 strain

	RSV F			Q VLP (HA)			RSV F + Q VLP (HA)		
Dose (µg)	0.5	1.5	6.0	0.5	1.5	6.0	0.5	1.5	6.0
GMT	10	10	10	113	106	368	61	139	368
				48-265	37-302	200-676	25-146	73-268	220-613
p value	p significance; combo versus single						Not significant		

Fig. 15C HAI response against the A/Victoria/361/11




Fig. 15D Tabular data for HAI response against the A/Victoria/361/11 strain

	RSV F			Q VLP (HA)			RSV F + Q VLP (HA)		
Dose (µg)	0.5	1.5	6.0	0.5	1.5	6.0	0.5	1.5	6.0
GMT	10	10	10	260	75	279	75	130	343
95% CI				75-896	28-198	121-643	35-159	67-252	189-621
p value	p significance; combo versus single						Not significant		

Fig. 15E HAI response against the B/Brisbane/60/08 strain




Fig. 15F Tabular Data for HAI response against the B/Brisbane/60/08 strain

	RSV F			Q VLP (HA)			RSV F + Q VLP (HA)		
Dose (μg)	0.5	1.5	6.0	0.5	1.5	6.0	0.5	1.5	6.0
GMT	10	10	10	15	13	35	7	17	23
95% CI				9-26	6-27	20-61	5-9	10-29	11-46
p value	p significance; combo versus single						Not significant		

Fig. 15G HAI response against the B/Massachusetts/2/12 strain




Fig. 15H Tabular Data for HAI response against the B/Massachusetts/2/12 strain

	RSV F			Q VLP (HA)			RSV F + Q VLP (HA)		
Dose (µg)	0.5	1.5	6.0	0.5	1.5	6.0	0.5	1.5	6.0
GMT	10	10	10	20	19	46	11	30	30
95% CI				10-39	8-43	15-144	7-18	14-64	18-52
p value	p significance; combo versus single						Not significant		

Fig. 16. Summary Table of Day 35 A/California HAI Titers

Group	RSV F (μg)	Q-Flu (HA μg)	A/Cal/H1N1 HAI Titers for animals 1-10										GMT	95% CI	p values vs Q-Flu+RSV
			1	2	3	4	5	6	7	8	9	10			
4	-	6	1280	80	160	160	640	320	640	640	640	320	368	200-676	0.881
5	-	1.5	5	160	10	160	320	160	320	160	160	320	106	37-302	0.807
6	-	0.5	80	20	640	320	160	40	320	160	20	160	113	48-265	0.205
7	6	6	1280	320	160	160	160	640	320	640	640	320	368	220-613	
8	1.5	1.5	80	160	160	160	640	320	20	160	160	80	139	73-268	
9	0.5	0.5	40	20	80	5	40	320	160	160	160	40	61	25-146	

Fig. 17. Summary Table of Day 35 A/Victoria HAI Titers

Group	RSV F (μg)	Q-Flu (HA μg)	A/Vic/H3N2 HAI Titers for animals 1-10										GMT	95% CI	p values vs Q-Flu +RSV
			1	2	3	4	5	6	7	8	9	10			
4	-	6	640	20	640	320	160	320	640	80	640	640	279	121-643	0.746
5	-	1.5	5	80	10	80	320	320	80	160	80	160	75	28-198	0.409
6	-	0.5	80	1280	640	5	320	320	2560	160	160	640	260	75-896	0.062
7	6	6	640	160	320	80	320	640	160	1280	640	320	343	189-621	
8	1.5	1.5	320	160	160	160	640	80	20	160	80	80	130	67-252	
9	0.5	0.5	160	20	40	20	80	160	40	320	40	320	75	35-159	

Fig. 18. Summary Table of Day 35 B/Brisbane HAI Titers

Group	RSV F (μg)	Q-Flu (HA μg)	B/Brisbane HAI Titers for animals 1-10										GMT	95% CI	p values vs Q-Flu +RSV
			1	2	3	4	5	6	7	8	9	10			
4	-	6	160	10	40	20	40	40	20	40	20	80	35	20-61	0.406
5	-	1.5	5	10	5	20	5	40	80	5	20	20	13	6-27	0.954
6	-	0.5	10	40	20	20	20	20	5	5	10	40	15	9-26	0.015
7	6	6	40	20	5	20	5	80	80	20	20	40	23	12-46	
8	1.5	1.5	20	5	40	40	40	20	10	10	20	10	17	10-29	
9	0.5	0.5	10	5	20	10	5	5	5	5	5	5	7	5-9	

Fig. 19. Summary Table of Day 35 B/Massachusetts HAI Titers

Grp	RSV F (µg)	Q-Flu (HA µg)	B/Massachusetts HAI Titers for animals 1-10										GMT	95% CI	p values vs Q-Flu +RSV
			1	2	3	4	5	6	7	8	9	10			
4	-	6	160	5	5	20	80	10	320	80	320	80	46	15-144	0.099
5	-	1.5	5	10	10	5	20	20	160	80	40	10	19	8-43	0.522
6	-	0.5	80	5	5	80	20	20	20	20	20	20	20	10-39	0.115
7	6	6	80	20	20	20	20	80	20	80	10	40	30	18-52	
8	1.5	1.5	10	20	320	20	40	80	10	20	40	20	30	14-64	
9	0.5	0.5	10	40	5	10	5	20	5	10	10	20	11	7-18	

Fig. 20. Summary Table of Day 21 RSV F IgG Titers

Grp	RSV F (µg)	Q-Flu (HA µg)	Anti-RSV F IgG Titers for animals 1-10										GMT	95% CI	p values vs Q-Flu +RSV
			1	2	3	4	5	6	7	8	9	10			
1	6	-	8,210	10,200	12,600	13,500	3,520	31,400	5,440	12,500	18,400	9,440	10,640	6882-16450	0.000
2	1.5	-	4,360	14,900	4,710	4,270	169	11,100	5,170	3,780	7,210	2,970	3,991	1671-9530	0.001
3	0.5	-	488	2,580	1,940	692	356	6,150	5,320	1,860	5,240	291	1,495	650-3436	0.000
7	6	6	22,500	24,500	41,800	26,400	30,300	57,400	51,400	35,000	37,500	25,900	33,627	26732-42299	
8	1.5	1.5	17,000	12,100	12,400	10,900	13,600	17,800	33,500	12,100	10,600	14,300	14,509	11374-18509	
9	0.5	0.5	3,920	8,190	5,590	5,740	3,100	10,200	10,300	9,130	8,730	7,290	6,745	5031-9044	

Fig. 21. Summary Table of Day 35 RSV F IgG Titers

Grp	RSV F (µg)	Q-Flu (HA µg)	Anti-RSV F IgG Titers for animals 1-10										GMT	95% CI	p values vs Q-Flu +RSV
			1	2	3	4	5	6	7	8	9	10			
1	6	-	20,500	392,000	144,000	177,000	47,100	71,600	106,000	508,000	95,400	66,300	108,932	54,901-108,932	0.042
2	1.5	-	14,300	40,800	42,500	267,000	90,800	265,000	143,000	30,800	43,400	48,700	65,632	33,161-129,898	0.042
3	0.5	-	2,600	19,200	139,000	14,700	55,500	78,300	132,000	90,200	123,000	66,600	46,087	18,572-114,366	0.062
7	6	6	576,000	254,000	218,000	255,000	219,000	192,000	312,000	438,000	249,000	300,000	284,639	223,418-362,637	
8	1.5	1.5	163,000	99,300	184,000	449,000	254,000	113,000	233,000	226,000	79,800	170,000	175,308	122,004-251,903	
9	0.5	0.5	182,000	134,000	56,100	109,000	79,800	243,000	113,000	95,900	145,000	48,300	108,178	75,665-154,662	

Fig. 22. Summary Table of Day 35 Competitive Palivizumab Antibody Titers

Grp	RSV F (µg)	Q-Flu (HA µg)	Palivizumab Competitive Titers for animals 1-10										GMT	95% CI	p values vs Q-Flu +RSV
			1	2	3	4	5	6	7	8	9	10			
1	6	-	20	279	99	103	60	87	95	256	101	82	95	56-161	0.001
2	1.5	-	20	50	53	261	95	172	143	44	65	68	76	44-130	0.018
3	0.5	-	20	20	127	20	48	90	96	75	97	88	55	33-94	0.002
7	6	6	467	218	225	210	189	263	292	418	316	208	268	215-334	
8	1.5	1.5	157	103	183	261	188	101	264	213	113	172	166	129-214	
9	0.5	0.5	152	140	94	113	104	206	147	115	169	68	125	99-157	

Fig. 23. Summary Table of Day 35 Microneutralization Titers

Grp	RSV F (µg)	Q-Flu (HA µg)	Microneutralization Titers for animals 1-10										GMT	95% CI	p values vs Q-Flu+RSV
			1	2	3	4	5	6	7	8	9	10			
1	6	-	40	160	40	160	20	80	20	160	40	40	57	32-102	0.285
2	1.5	-	40	80	40	20	40	80	40	40	40	40	43	32-57	0.057
3	0.5	-	10	20	40	20	20	40	40	20	20	40	25	18-34	0.004
7	6	6	160	80	80	80	80	40	40	320	160	80	92	58-145	
8	1.5	1.5	40	40	80	40	80	80	80	40	80	80	61	47-78	
9	0.5	0.5	40	40	80	20	80	40	80	40	40	80	49	35-69	